Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Fomepizole, an effective antidote to ethylene glycol poisoning

March 29, 1999

Dual dopamine D1/D5 antagonist blocks the rewarding effects of cocaine in humans

March 24, 1999

Bupropion more effective than nicotine patches in smoking cessation therapy

March 8, 1999

Glaxo Wellcome seeks approval for Zyban in the E.U.

March 4, 1999

Multiple methods of nicotine replacement increase abstinence rates in smokers

Feb. 24, 1999

Cantab completes acquisition of drug addiction programs from ImmuLogic

Feb. 3, 1999

Studies in knockout mice support the role of CB1 receptor in opiate addiction

Jan. 26, 1999

Potent and selective DAT ligand identified by RTI and Emory University

Jan. 22, 1999

Novel pure mu/kappa-opioid receptor antagonist as a lead in the field of drug abuse therapy

Jan. 20, 1999

Orphan drug for iron overload offered for licensing by Biomedical Frontiers

Jan. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...